IDEXX Laboratories, Inc. (IDXX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $568.78 (+1.42%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 5, 2026 | Glen Santangelo | Barclays | $800.00 | +40.7% |
| Feb 3, 2026 | Andrea Alfonso | UBS | $730.00 | +28.3% |
| Dec 8, 2025 | Glen Santangelo | Barclays | $850.00 | +49.4% |
| Nov 4, 2025 | Keith Devas | Jefferies | $830.00 | +45.9% |
| Nov 3, 2025 | Jonathan Block | Stifel Nicolaus | $775.00 | +36.3% |
| Oct 31, 2025 | Jonathan Block | Stifel Nicolaus | $700.00 | +23.1% |
| Oct 1, 2025 | Andrea Alfonso | UBS | $720.00 | +26.6% |
| Jun 24, 2024 | Jonathan Block | Stifel Nicolaus | $510.00 | -10.3% |
| May 6, 2022 | Balaji Prasad | Barclays | $700.00 | +23.1% |
Top Analysts Covering IDXX
IDXX vs Sector & Market
| Metric | IDXX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.40 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +35.9% | +1150.2% | +14.9% |
| P/E Ratio | 43.52 | 6.83 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4.66B | $4.68B | $4.72B | 11 |
| 2027-06-30 | $1.29B | $1.30B | $1.32B | 6 |
| 2027-09-30 | $1.28B | $1.29B | $1.31B | 4 |
| 2027-12-31 | $1.26B | $1.28B | $1.29B | 7 |
| 2028-03-31 | $1.26B | $1.28B | $1.29B | 3 |
| 2028-06-30 | $1.43B | $1.45B | $1.46B | 5 |
| 2028-09-30 | $1.42B | $1.44B | $1.45B | 3 |
| 2028-12-31 | $1.40B | $1.41B | $1.43B | 6 |
| 2029-03-31 | $1.36B | $1.38B | $1.39B | 4 |
| 2029-12-31 | $6.09B | $6.15B | $6.22B | 5 |
| 2030-12-31 | $6.93B | $7.00B | $7.08B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $14.36 | $14.51 | $14.68 | 11 |
| 2027-06-30 | $4.36 | $4.43 | $4.49 | 3 |
| 2027-09-30 | $4.19 | $4.26 | $4.32 | 4 |
| 2027-12-31 | $3.87 | $3.93 | $3.98 | 3 |
| 2028-03-31 | $4.08 | $4.14 | $4.20 | 4 |
| 2028-06-30 | $5.14 | $5.22 | $5.29 | 4 |
| 2028-09-30 | $4.88 | $4.95 | $5.02 | 6 |
| 2028-12-31 | $4.42 | $4.49 | $4.55 | 4 |
| 2029-03-31 | $4.57 | $4.64 | $4.70 | 3 |
| 2029-12-31 | $21.14 | $21.40 | $21.71 | 6 |
| 2030-12-31 | $25.90 | $26.21 | $26.59 | 6 |
Frequently Asked Questions
What is the analyst consensus for IDXX?
The consensus among 10 analysts covering IDEXX Laboratories, Inc. (IDXX) is Buy with an average price target of $784.38.
What is the highest price target for IDXX?
The highest price target for IDXX is $850.00, set by Glen Santangelo at Barclays on 2025-12-08.
What is the lowest price target for IDXX?
The lowest price target for IDXX is $510.00, set by Jonathan Block at Stifel Nicolaus on 2024-06-24.
How many analysts cover IDXX?
10 analysts have issued ratings for IDEXX Laboratories, Inc. in the past 12 months.
Is IDXX a buy or sell right now?
Based on 10 analyst ratings, IDXX has a consensus rating of Buy (2.40/5) with a +35.9% upside to the consensus target of $784.38.
What are the earnings estimates for IDXX?
Analysts estimate IDXX will report EPS of $14.51 for the period ending 2026-12-31, with revenue estimated at $4.68B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.